Belimumab Dose Spacing May Be an Option for Selected Patients With SLE in Sustained Remission

As reported on MedScape, gradually extending the interval between belimumab doses may allow carefully selected patients with systemic lupus erythematosus (SLE) in long-term remission to reduce treatment exposure (and in…

Continue Reading Belimumab Dose Spacing May Be an Option for Selected Patients With SLE in Sustained Remission

FDA Grants Breakthrough Therapy Designation to Pemafibrate for Primary Biliary Cholangitis

As reported on PR Newswire, the US Food and Drug Administration has granted Breakthrough Therapy designation to Kowa’s investigational therapy K-808 (pemafibrate) for primary biliary cholangitis (PBC), the company announced.…

Continue Reading FDA Grants Breakthrough Therapy Designation to Pemafibrate for Primary Biliary Cholangitis

Enfortumab Vedotin/Pembrolizumab Regimen Outperforms Neoadjuvant Chemotherapy in Resectable MIBC

As reported on The ASCO Post, perioperative treatment with enfortumab vedotin-ejfv plus pembrolizumab resulted in superior event-free survival, overall survival, and pathologic response rates compared with neoadjuvant cisplatin/gemcitabine in cisplatin-eligible…

Continue Reading Enfortumab Vedotin/Pembrolizumab Regimen Outperforms Neoadjuvant Chemotherapy in Resectable MIBC

Axsome Launches Phase 3 CLARITY Study of Solriamfetol for Depression Patients Experiencing Daytime Sleepiness

As reported by The Manila Times, Axsome Therapeutics has announced the initiation of its Phase 3 CLARITY clinical trial evaluating solriamfetol as a potential treatment for adults with major depressive…

Continue Reading Axsome Launches Phase 3 CLARITY Study of Solriamfetol for Depression Patients Experiencing Daytime Sleepiness